Available Technologies
# of Displayed Technologies: 3 / 3
Applied Category Filter (Click To Remove): Oncology
Selective Estrogen Receptor Beta Agonists
TS-062681 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: OSU Wexner Medical Center
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: College of Pharmacy
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Glucose Transporter Inhibitors (GLUT1 Inhibitors)
TS-014734 — A potential cancer treatment that suppresses the ability for cancer cells to intake glucose, thereby hampering cancer cell production.
A fundamental property of neoplastic cells is the shift in cellular metabolism from oxidative phosphorylation to aerobic glycolysis. This glycolytic shift, called the Warburg effect, enables cancer cells to adapt to low-oxygen microenvironments, to generate biosynthetic building blocks for cell pr…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Kulp, Samuel; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
